北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 放射治疗科  > 期刊论文
学科主题: 放射医学
题名:
宫颈癌同期放化疗每周单药顺铂的Ⅰ和Ⅱ期临床试验
其他题名: A phase Ⅰ / Ⅱ study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy
作者: 李晓梅1; 王庆国1; 张福泉1; 胡克1; 张敏1; 李洪振1; 赵勍1; 秦尚斌1; 侯栋梁1; 高献书1
关键词: 顺铂 ; 最大耐受剂量 ; 宫颈肿瘤/同期放化疗法 ; 不良反应 ; Cisplatin ; Maximum tolerated dose ; Cervical neoplasms/concurrent radiochenmotherapy ; Toxicity
刊名: 中华放射肿瘤学杂志
发表日期: 2012
DOI: 10.3760/cma.j.issn.1004-4221.2012.01.015
卷: 21, 期:1, 页:52-55
收录类别: 中国科技核心期刊 ; 中文核心期刊 ; CSCD
文章类型: Journal Article
摘要: 目的 探讨中晚期宫颈癌患者同期放化疗中适合中国人的顺铂单药化疗每周方案剂量.方法 ⅠB2~ⅣA期需放疗的宫颈癌患者为研究对象.Ⅰ期临床试验(15例)为剂量递增试验,顺铂剂量以20、25、30、35、40 mg/m2逐渐递增(≥3例/剂量),40 mg/m2后不再增加剂量.依据Ⅰ期临床试验所得出的最大耐受剂量(40 mg/m2)进行Ⅱ期临床试验(36例).盆腔放疗采用三维适形方法.结果 Ⅰ期临床试验剂量递增至顺铂40 mg/m2未出现限制性不良反应.Ⅱ期临床试验中住院的9例患者都完成了6周化疗,门诊治疗的27例患者18例完成6周化疗,19例完成5周化疗,25例完成4周化疗.所有患者都完成了放疗.主要不良反应为1、2级胃肠道反应与白细胞减少.结论 应用顺铂单药每周方案同期放化疗中晚期宫颈癌,大部分中国人能耐受40 mg/m2的同期化疗剂量,对不能住院治疗体质较弱者化疗剂量应适当减量. Objective To define the maximum tolerated dose (MTD) of weekly cisplatin in concurrent chemoradiotherapy for Chinese cervical carcinoma.Methods Cervical carcinoma of stage ⅠB2- ⅣA were eligible for the study.Phase Ⅰ study was dose-escalation trial with 15 patients.All patients received whole pelvic radiotherapy with three dimentional conformal radiotherapy technique. Concurrent cisplatin started from the dose of 20 mg/m2 to 25 mg/m2,30 mg/m2,35 mg/m2,40 mg/m2 for the weekly schedule ( ≥3 patients per dose group) and the doses were steadily escalated to 40 mg/.m2.If the dose was increased to 40 mg/m2 without dose-limiting toxicity ( DLT),40 mg/m2 would be the maximum tolerated dose (MTD).According to the MTD dose from Phase Ⅰ study,we conducted phase Ⅱ clinical trial with 36 patients.Results In Phase Ⅰ study,cisplatin dose was escalated to 40 mg/m2 and DLT had not been reached.Thirty-six patients in Phase Ⅱ study included 9 inpatients and 27 outpatients.All 9 inpatients completed 6 cycles of chemotherapy. In 27 outpatients,18 patients (66%) completed 6 cycles of chemotherapy,19 patients (70%) completed 5 cycles and 25 patients (92%) completed 4 cycles of chemotherapy.All patients completed radiotherapy.Major adverse effects were grade 1 and 2 gastrointestinal toxicities and neutropenia.Conclusions Weekly 40 mg/m2 cisplatin concurrent with radiotherapy is well tolerated when given to Chinese patients with cervical carcinoma. For outpatients with poor performance status,the cisplatin dose needs to be reduced.
语种: 中文
原文出处: 查看原文
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/42174
Appears in Collections:北京大学第一临床医学院_放射治疗科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.100034, 北京大学第一医院放疗科
2.中国医学科学院北京协和医学院协和医院放疗科
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[李晓梅]'s Articles
[王庆国]'s Articles
[张福泉]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[李晓梅]‘s Articles
[王庆国]‘s Articles
[张福泉]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace